Drug design of GPCR ligands using physicogenetics and chemogenomics - principles and case studies

Current Topics in Medicinal Chemistry

Volumn 11, Issue 15, 2011, Pages 1882-1901

  Frimurer, Thomas M ^a   Thomas, Högberg ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LEO PHARMA A S   (Denmark)

Author keywords

7tm receptor; Beta2 receptor; Binding pocket; Chemogenomics; Crth2 receptor; Mch1 receptor; Physicogenetics; Virtual screening

Indexed keywords

2 (1 PHENYL 1H PYRAZOLE 4 CARBONYL)PHENOXYACETIC ACID; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 BROMO N [1 (4 FLUOROBENZYL) 2 PYRROLIDINYLMETHYL] 2,3 DIMETHOXYBENZAMIDE; APELIN RECEPTOR; BENZAMIDE; CANDESARTAN; CARAZOLOL; CYANOPINDOLOL; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ETICLOPRIDE; ETICLOPRODE; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE; INDOMETACIN; LOSARTAN; MELANIN CONCENTRATING HORMONE RECEPTOR; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; PHENOXYACETIC ACID DERIVATIVE; PINDOLOL; PROSTAGLANDIN D2; SB 2822411; SEROTONIN RECEPTOR; SEVEN TRANSMEMBRANE RECEPTOR; TIMOLOL; UNCLASSIFIED DRUG;

ARTICLE; CHEMOGENOMICS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; FRAGMENT BASED DRUG DESIGN; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DATABASE; HEALTH CARE FACILITY; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; INFLAMMATORY CELL; LIGAND BINDING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACOGENOMICS; PHARMACOPHORE; PHYLOGENY; PHYSICOGENETICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; VIRTUAL REALITY;

ANIMALS; BINDING SITES; DATABASES, FACTUAL; DRUG DESIGN; GENOMICS; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 79960578304     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796391258     Document Type: Article

References (110)

1. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1, 727-730.
2. Overington, J.P.; Al-Lazikani, B.; Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov., 2006, 5, 993-996. Drug Information Online. www.drugs.com/top200.html.
3. Tyndall, J.D.; Sandilya, R. GPCR agonists and antagonists in the clinic. Med Chem., 2005, 1, 405-421.
4. Jacoby, E., Bouhelal, R., Gerspacher, M.; Seuwen, K. The 7 TM G- protein-coupled receptor target family. ChemMedChem, 2006, 1, 761-782.
5. Fredriksson, R.; Lagerström, M. C.; Lundin, L. G.; Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63, 1256-1272.
6. Lagerström, M.C.; Schiöth, H.B. Structural diversity of G protein coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov., 2008, 7, 339-357.
7. Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther., 2004, 103, 21-80.
8. GPCRDB - information system for G protein-coupled receptors: http://www.gpcr.org/7tm/
9. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-745.
10. Okada, T.; Sugihara, M.; Bondar, A. N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J. Mol. Biol., 2004, 342, 571-583.
11. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem., 2002, 3, 928-944.
12. Klabunde, T. Chemogenomics approaches to ligand design. In Ligand Design for G Protein-coupled Receptors. Ch. 7, Wiley-VCH, Great Britain, 2006, pp. 115-135.
13. Rognan, D. Chemogenomic approaches to rational drug design. Br. J. Pharmacol., 2007, 152, 38-52.
14. Jimonet, P.; Jäger, R. Strategies for designing GPCR-focused libraries and screening sets. Curr. Opin. Drug Discov. Devel., 2004, 7, 325-333.
15. Weill, N.; Rognan, D. Development and validation of a novel pro-tein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands. J. Chem. Inf. Model., 2009, 49, 1049-1062.
16. Jacoby, E. Designing compound libraries targeting GPCRs. Ernst Schering Found. Symp. Proc., 2006, 2, 93-103.
17. Klabunde, T.; Jäger, R. Chemogenomics approaches to G-protein coupled receptor lead finding. Ernst Schering Res. Found. Workshop, 2006, 58, 31-46.
18. Soltanshahi, F.; Mansley, T.E.; Choi, S., Clark, R.D. Balancing focused combinatorial libraries based on multiple GPCR ligands. J. Comput. Aided Mol. Des., 2006, 20, 529-538.
19. Albert, J.S.; Blomberg, N.; Breeze, A.L.; Brown, A.J.; Burrows, J.N.; Edwards P.D.; Folmer, R.H.; Geschwindner, S.; Griffen, E.J.; Kenny, P.W.; Nowak, T.; Olsson, L.L.; Sanganee, H.; Shapiro, A.B. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr. Top. Med. Chem., 2007, 7, 1600-1629.
20. Siegal, G.; Hollander, J.G. Target Immobilization and NMR Screening of Fragments in Early Drug Discovery. Curr. Top. Med. Chem., 2009, 9, 1736-1745.
21. Jacob L, Hoffmann B, Stoven V, Vert JP. Virtual screening of GPCRs: an in silico chemogenomics approach. BMC Bioinformat-ics., 2008, 9, 363 (doi:10.1186/1471-2105-9-363).
22. Evers, A.; Klebe, G. Successful virtual screening for a submicro-molar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem., 2004, 47, 5381-5392.
23. Evers A, Hessler G, Matter H, Klabunde T. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. J. Med. Chem., 2005, 48, 5448-5465.
24. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem., 2005, 48, 1088-1097.
25. Bologa, C. G.; Revankar, C. M.; Young, S. M.; Edwards, B. S.; Arterburn, J. B.; Kiselyov, A. S.; Parker, M. A.; Tkachenko, S. E.; Savchuck, N. P.; Sklar, L. A.; Oprea, T. I.; Prossnitz, E. R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol., 2006, 2, 207-212.
26. Becker, O. M.; Dhanoa, D. S.; Marantz, Y.; Chen, D.; Shacham, S.; Cheruku, S.; Heifetz, A.; Mohanty, P.; Fichman, M.; Sharadendu, A.; Nudelman, R.; Kauffman, M.; Noiman, S. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J. Med. Chem., 2006, 49, 3116-3135.
27. Kortagere S, Welsh WJ. Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors. J. Comput. Aided Mol. Des., 2006, 20, 789-802.
28. Kellenberger, E.; Springael, J. Y.; Parmentier, M.; Hachet-Haas, M.; Galzi, J. L.; Rognan, D. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J. Med. Chem., 2007, 50, 1294-1303.
29. Tikhonova, I. G.; Sum, C. S.; Neumann, S.; Engel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J. Med. Chem., 2008, 51, 625-633.
30. Engel, S.; Skoumbourdis, A. P.; Childress, J.; Neumann, S.; Deschamps, J. R.; Thomas, C. J.; Colson, A. O.; Costanzi, S.; Ger-shengorn, M. C. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. J. Am. Chem. Soc., 2008, 130, 5115-5123.
31. Klabunde, T.; Giegerich, C.; Evers, A. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. J. Med. Chem., 2009, 52, 2923-2932.
32. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Ko-bilka, B. K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature, 2007, 450, 383-387.
33. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S.G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 2007, 318, 1258-1265.
34. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields high resolution structural insights into beta2-adrenergic receptor function. Science, 2007, 318, 1266-1273.
35. Hanson, M.A.; Cherezov, V.; Griffith, M.T.; Roth, C.B.; Jaakola, V. P.; Chien, E.Y.; Velasquez, J.; Kuhn, P.; Stevens, R.C. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure, 2008, 16, 897-905.
36. Warne, T.; Serrano-Vega, M.J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491.
37. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322, 1211-1217.
38. Forrest, L. R.; Tang, C. L.; Honig, B. On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins. Biophys. J., 2006, 91, 508-517.
39. Costanzi, S. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J. Med. Chem., 2008, 51, 2907-2914.
40. Mobarec, J.C.; Sanchez, R.; Filizola, M. Modern homology modeling of g-protein coupled receptors: Which structural template to use? J. Med. Chem., 2009, 52, 5207-5216.
41. Reynolds, K.A.; Katritch, V.; Abagyan, R. Identifying conforma-tional changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators. J. Comput. Aided Mol. Des., 2009, 23, 273-288.
42. Kolb, P.; Rosenbaum, D.M.; Irwin, J.J.; Fung, J.J.; Kobilka, B.K.; Shoichet, B.K. Structure-based discovery of beta2-adrenergic receptor ligands. Proc. Natl. Acad. Sci. USA, 2009, 106, 6843-6848.
43. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Sabio M, Jones K, Topiol S. Bioorg. Med. Chem. Lett., 2008, 18, 5391-5395.
44. Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H. W.; Hofmann, K. P.; Ernst, O. P. Crystal structure of op-sin in its G-protein-interacting conformation. Nature, 2008, 455, 497-502.
45. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H. W.; Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor op-sin. Nature, 2008, 454, 183-187.
46. Schwartz, T. W.; Hubbell, W. L. Structural biology: A moving story of receptors. Nature, 2008, 455, 473-474.
47. Jain, A.N. Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation. J. Comput. Aided. Mol. Des., 2009, 6, 355-374.
48. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins, 2002, 47, 409-443.
49. Goddard, W.A.; Abrol, R.; Kim, S.K.; Li, Y.; Trzaskowski, B.; Griffith, A.R. Predicted 3D structures for adenosine receptors bound to ligands; comparison to the crystal structure. J. Struct. Biol. 2010, 170, 10-20.
50. Surgand, J.S., Rodrigo, J.; Kellenberger, E., Rognan, D. A che-mogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins, 2006, 62, 509-538.
51. Klabunde, T. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br. J. Pharmacol., 2007, 152, 5-7.
52. Gloriam, D.E.; Foord, S.M.; Blaney, F.E.; Garland, S.L. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem., 2009, 52, 4429-4442.
53. de Graaf, C.; Foata, N.; Engkvist, O.; Rognan, D. Molecular modeling of the second extracellular loop of G-protein coupled receptors and its implication on structure-based virtual screening. Proteins, 2008, 71, 599-620.
54. Frimurer, T.M.; Ulven, T.; Högberg, T.; Elling, C.E. A pseudo-sequence method for comparing 7TM receptors with respect to the physicochemical properties of their binding sites. PCT Int. Appl., 2004, WO 2004079625.
55. Frimurer, T.M.; Ulven, T.; Elling, C.E.; Gerlach, L.O.; Kostenis, E.; Högberg, T. A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg. Med. Chem. Let., 2005, 15, 3707-3712.
56. Hellberg, S.; Sjöström, M.; Skagerberg, B.; Wold, S. Peptide quantitative structure-activity relationships, a multivariate approach. J. Med. Chem., 1987, 30, 1126-1135.
57. Collantes, E.R.; Dunn, W.J. 3rd. Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues. J. Med. Chem., 1995, 38, 2705-2713.
58. Sandberg, M.; Eriksson, L.; Jonsson, J.; Sjöström, M.; Wold, S. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J. Med. Chem., 1998, 41, 2481-2491.
59. Zaliani, A.; Gancia, E. MS-WHIM scores for amino acids: A new 3D-description for peptide QSAR and QSPR studies. J. Chem. Inf. Comp. Sci., 1999, 39, 525-533.
60. Matter, H. A validation study of molecular descriptors for the rational design of peptide libraries. J. Peptide Res., 1998, 52, 305-314.
61. Sak, K.; Karelson, M.; Järv, J. Modelling of the amino acid side chain effects on peptide conformation. Bioorg. Chem., 1999, 27, 434-442.
62. Norinder, U.; Svensson, P. Descriptors for amino acids using Mol-Surf parametrization. J. Comp. Chem., 1998, 19, 51-59.
63. Norinder, U. Theoretical amino acid descriptors. Application to bradykinin potentiating peptides. Peptides 1991, 12, 1223-1227.
64. Martin, Y.C.; Kofron, J.L.; Traphagen, L.M. Do structurally similar molecules have similar biological activity? J. Med. Chem., 2002, 45, 4350-4358.
65. Ballesteros, J.A.; Weinstein, H. Analysis and refinement of criteria for predicting the structure and relative orientations of transmem-branal helical domains. Biophys. J., 1992, 62, 107-109;
66. Ballesteros, J.A.; Weinstein, H.; Stuart, C.S. Methods Neurosci., 1995, 25, 366-428.
67. Baldwin, J.M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J., 1993, 12, 1693-1703.
68. Baldwin, J.M.; Schertler, G.F.; Unger, V.M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol., 1997, 272, 144-164.
69. Schwartz, T.W. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr. Opin. Biotechnol., 1994, 5, 434-444.
70. Strader, C.D.; Candelore, M.R.; Hill, W.S.; Sigal, I.S.; Dixon, R.A. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J. Biol. Chem., 1989, 264, 13572-13578.
71. Wieland, K.; Zuurmond, H.M.; Krasel, C.; Ijzerman, A.P.; Lohse, M.J. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc. Natl. Acad. Sci. USA, 1996, 93, 9276-9281.
72. Kikkawa, H.; Isogaya, M.; Nagao, T.; Kurose, H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol. Pharmacol., 1998, 53, 128-134.
73. Kanagarajadurai, K.; Malini, M.; Bhattacharya, A.; Panicker, MM.; Sowdhamini, R. Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding. Mol. BioSyst., 2009, 5, 1877-1888.
74. Holst, B.; Nygaard, R.; Valentin-Hansen, L.; Bach, A.; Engelstoft, M.S.; Petersen, P.S.; Frimurer, T.M.; Schwartz, T.W. A Conserved aromatic lock for the Tryptophan Rotameric Switch in TM-VI of 7TM receptors. J. Biol. Chem. 2010, 285, 3973-3985.
75. Nygaard, R.; Frimurer, T.M.; Holst, B.; Rosenkilde, M.M.; Schwartz, T.W. Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol. Sci., 2009, 30, 249-259.
76. Elling, C.E.; Frimurer, T.M.; Gerlach, L.O.; Jørgensen, R.; Holst, B.; Schwartz, T.W. Metal ion site engineering indicates a global toggle switch model for seven-transmembrane receptor activation. J. Biol. Chem., 2006, 281, 17337-17346.
77. Liapakis, G.; Ballesteros, J.A.; Papachristou, S.; Chan, W.C.; Chen, X.; Javitch, J.A. The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J. Biol. Chem., 2000, 275, 37779-37788.
78. Edvardsen, O.; Reiersen, A.L.; Beukers, M.W.; Kristiansen, K. tGRAP, the G-protein coupled receptors mutant database. Nucleic Acids Res., 2002, 30, 361-363.
79. Cavasotto, C.N.; Orry, A.J.; Abagyan, R.A. Structure-based identification of binding sites, native ligands and potential inhibitors for G-protein coupled receptors. Proteins, 2003, 51, 423-433.
80. Goddard, W.A.; Abrol, R. 3-Dimensional structures of G protein-coupled receptors and binding sites of agonists and antagonists. J. Nutr., 2007, 137 (6 Suppl 1), 1528S-1538S
81. Lee, Y.H.; Naider, F.; Becker, J.M. Interacting residues in an activated state of a G protein-coupled receptor. J. Biol. Chem., 2006, 281, 2263-2272.
82. Hawtin, S.R.; Simms, J.; Conner, M.; Lawson, Z.; Parslow, R.A.; Trim, J.; Sheppard, A.; Wheatley, M. Charged extracellular residues, conserved throughout a G-protein-coupled receptor family, are required for ligand binding, receptor activation, and cell-surface expression. J. Biol. Chem., 2006, 281, 38478-38488.
83. Hillmann, P.; Ko, G.Y.; Spinrath, A.; Raulf, A.; von Kügelgen, I.; Wolff, S.C.; Nicholas, R.A.; Kostenis, E.; Höltje, H.D.; Müller, C.E. Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J. Med. Chem., 2009, 52, 2762-2775.
84. Various similarity scores are described in: Press, W.H; Flannery, B.P.; Teukolsky, S.A.; Vettering, W.T. Numerical recipes: The art of scientific computing; Cambridge University Press, 1986.
85. von Korff, M; Hilpert, K. Assessing the predictive power of unsu-pervised visualization techniques to improve the identification of GPCR-focused compound libraries. J. Chem. Inf. Model. 2006, 46, 1580-1587.
86. Schneider, P.; Tanrikulu, Y.; Schneider, G. Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr. Med. Chem., 2009, 16, 258-266.
87. Kupas, K.; Ultsch, A.; Klebe, G. Large scale analysis of protein-binding cavities using self-organizing maps and wavelet-based surface patches to describe functional properties, selectivity discrimination, and putative cross-reactivity. Proteins, 2008, 71, 1288-1306.
88. Pettipher, R. The roles of the prostaglandin D2 receptors DP1 and CRTH2 in promoting allergic responses. Br. J. Pharmacol., 2008, 153 (Suppl 1), S191-199.
89. Kostenis, E, Ulven, T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med., 2006, 12, 148-158.
90. Medina, J.C.; Liu, J. PGD2 antagonists. Ann. Rep. Med. Chem., 2006, 41, 221-225.
91. Ulven, T.; Kostenis, E. Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr. Top. Med. Chem., 2006, 6, 1427-44.
92. Hirai, H.; Tanaka, K.; Takano, S.; Ichimasa, M.; Nakamura, M.; Nagata, K. Cutting edge: agonistic effect of indomethacin on a pro-staglandin D2 receptor, CRTH2. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J. Immunol., 2002, 168, 981-985.
93. Hirai, H.; Tanaka, K.; Yoshie, O.; Ogawa, K.; Kenmotsu, K.; Ta-kamori, Y.; Ichimasa, M.; Sugamura, K.; Nakamura, M.; Takano, S.; Nagata, K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med., 2001, 193, 255-261.
94. Ulven, T.; Receveur, J.-M.; Grimstrup, M.; Rist O.; Frimurer, T.M.; Gerlach, L.-O.; Mathiesen, J.M.; Kostenis, E.; Uller, L.; Hö-gberg, T. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J. Med. Chem., 2006, 49, 6638-6641.
95. Rist O.; Grimstrup, M.; Receveur, J.-M.; Frimurer, T.M.; Ulven, T.; Kostenis, E.; Högberg, T. Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1. Bioorg. Med. Chem. Let., 2010, 20, 1177-1180.
96. Grimstrup, M.; Rist O.; Receveur, J.-M.; Frimurer, T.M.; Ulven, T.; Kostenis, E.; Mathiesen, J.M.; Högberg, T. Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg. Med. Chem. Let., 2010, 20, 1181-1185.
97. Grimstrup, M.; Receveur, J.-M; Rist O.; Frimurer, T.M.; Aadal Nielsen, P.; Mathiesen, J.M.; Högberg, T. Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists. Bioorg. Med. Chem. Let., 2010, 20, 1638-1641.
98. Rivera, G.; Bocanegra-García, V.; Galiano, S.; Cirauqui, N.; Ceras, J.; Pérez, S.; Aldana, I.; Monge, A. Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharma-cologic treatment of obesity. Curr. Med. Chem., 2008, 15, 1025-1043.
99. Judd, A.S.; Souers, A.J.; Kym, P.R. Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity. Curr. Top. Med. Chem., 2008, 8, 1152-1157.
100. Takekawa, S.; Asami, A.; Ishihara, Y.; Terauchi, J.; Kato, K.; Shi-momura, Y.; Mori, M.; Murakoshi, H.; Kato, K.; Suzuki, N.; Ni-shimura, O.; Fujino, M. T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist Eur. J. Pharmacol., 2002, 438, 129-135.
101. Högberg, T. The development of dopamine D2-receptor selective antagonists. Drug Design Discov., 1993, 9, 333-350.
102. Receveur, J.-M.; Bjurling, E.; Ulven, T.; Little, P.B.; Nørregaard, P. K.; Högberg, T. 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg. Med. Chem. Let., 2004, 14, 5075-5080.
103. Ulven, T.; Frimurer, T.M.; Receveur, J.M.; Little, P.B.; Rist O.; Nørregaard, P.K.; Högberg, T. 6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode. J. Med. Chem., 2005, 48, 5684-5697.
104. Ulven, T.; Little, P.B.; Receveur, J.M.; Frimurer, T.M.; Rist O.; Nørregaard, P.K.; Högberg, T. 6-Acylamino-2-amino-4-methylquinolines as potent melanin-concentrating hormone 1 receptor antagonists: structure-activity exploration of eastern and western parts. Bioorg. Med. Chem. Let., 2006, 16, 1070-1075.
105. Trivedi, B.K.; Low, J.E.; Carson, K.; LaRosa, G.J. Chemokines: targets for novel therapeutics. Ann. Rep. Med. Chem., 2000, 35, 191-200.
106. Krumrine, J.; Frimurer, T.M.; Högberg, T. Using GPCR target and ligand information in drug discovery. Gordon Research Conference in Computer Aided Drug Design. 2005, July 31 - August 5.
107. ChEMBL - database of bioactive drug-like small molecules with structures, calculated properties and abstracted bioactivities: http://www.ebi.ac.uk/chembldb/index.php
108. Unity 2D fingerprints available from Tripos Inc. at http://www.tripos.com.
109. Tiikkainen, P.; Poso, A.; Kallioniemi, O. Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. J. Comput. Aided Mol. Des., 2009, 23, 227-239.
110. Berkhout, T.A.; Blaney, F.E.; Bridges, A.M.; Cooper, D.G.; Forbes, I.T.; Gribble, A.D.; Groot, P.H.; Hardy, A.; Ife, R.J.; Kaur, R.; Moores, K.E.; Shillito, H.; Willetts, J.; Witherington, J. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J. Med. Chem., 2003, 46, 4070-4086.